CDTRP Special Webinar – What is known and unknown about COVID-19 therapeutics for transplant recipients?

Since the start of the pandemic, CDTRP has leveraged its infrastructure to understand the ongoing needs of patients, families, and donors (PFD). Our PFD partners have told us that understanding the effectiveness of treatments and their implications for the diverse spectrum of transplant recipients is a priority for them and their families. With the ongoing pandemic and changes in variants, join us to learn the latest in research and therapeutic development from experts Dr. Sara Belga and Dr. Catherine Burton.

This webinar is an opportunity to get the latest data/facts on and to ask Drs. Belga and Burton questions about COVID-19 therapeutics.

  • Wednesday, January 25, 2023
  • 3 – 4 pm EST
About Dr. Sara Belga

Dr. Belga is a Clinical Assistant Professor at the University of British Columbia (UBC). She received her medical degree from the University of Lisbon. She completed her training in Infectious Disease at the University of Alberta followed by a one-year fellowship in Transplant Infectious Disease at the same institution. Additionally, she rotated through the Immunocompromised Host Infectious Diseases service at Stanford Hospital and Transplant and Oncology Infectious Diseases service at the Brigham and Women’s Hospital and Dana Farber Cancer Institute.  She joined the Transplant Infectious Disease program for the province of British Columbia in 2019. Her clinical responsibilities include the care of pre- and post-transplant patients at Vancouver General Hospital. Her research interests include latent viral infections in transplantation and immune monitoring strategies in transplantation, that allow personalized medicine and individualized approaches to care. Her other interests include Epidemiology, Biostatistics, Clinical Trials and Drug Safety.

About Dr. Catherine Burton

Dr. Catherine Burton is an Assistant Professor at the University of Alberta. Dr. Burton’s primary areas of research is in immunizations and vaccine preventable diseases in children, especially immunocompromised children who often require alternate vaccine schedules and/or vaccine dosing to ensure optimal protection. Much of her immunization related research is in collaboration with national networks including the Special Immunization Clinic network and the Canadian Donation and Transplantation Research Program with current studies looking at the use of live varicella vaccine in children who have had solid organ transplants and evaluating the immunogenicity and safety of COVID-19 vaccines in children who have had organ transplants.